44 related articles for article (PubMed ID: 10216474)
1. The relationship between carboplatin AUC and serum thrombopoietin kinetics in patients with lung cancer.
Miyazaki M; Fujiwara Y; Isobe T; Yamakido M; Kato T; Miyazaki H
Anticancer Res; 1999; 19(1B):667-70. PubMed ID: 10216474
[TBL] [Abstract][Full Text] [Related]
2. Investigating the relationship between serum thrombopoietin kinetics and the platelet-sparing effect: A clinical pharmacological evaluation of combined paclitaxel and carboplatin in patients with non-small cell lung cancer.
Daga H; Isobe T; Miyazaki M; Fujitaka K; Kondo K; Kohno N
Oncol Rep; 2004 Jun; 11(6):1225-31. PubMed ID: 15138560
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of biweekly paclitaxel and carboplatin for frail patients with advanced non-small cell lung cancer.
Yanagitani N; Tsuchiya S; Kaira K; Sunaga N; Tsuchiya Y; Sato K; Watanabe S; Nomura S; Sakai S; Saito R; Mori M
Am J Clin Oncol; 2007 Oct; 30(5):487-91. PubMed ID: 17921708
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel, carboplatin, and vinorelbine in the treatment of advanced non-small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Burris HA; Morrissey LH; Thomas M; Erland JB; Butts JA; Joseph G; Kalman L; Greco FA
Cancer J; 2000; 6(3):151-6. PubMed ID: 10882330
[TBL] [Abstract][Full Text] [Related]
5. Serum thrombopoietin levels in patients with reactive thrombocytosis due to lung cancer and in patients with essential thrombocythemia.
Werynska B; Ramlau R; Podolak-Dawidziak M; Jankowska R; Prajs I; Usnarska-Zubkiewicz L; Kuliczkowski K
Neoplasma; 2003; 50(6):447-51. PubMed ID: 14689068
[TBL] [Abstract][Full Text] [Related]
6. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.
Belani CP; Ramalingam S; Perry MC; LaRocca RV; Rinaldi D; Gable PS; Tester WJ
J Clin Oncol; 2008 Jan; 26(3):468-73. PubMed ID: 18202422
[TBL] [Abstract][Full Text] [Related]
7. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
Glorieux P; Ortmanns P; Marien S; Degives R; Degraeve D; Potvin M; Grauwels D; Schallier D
Anticancer Res; 2001; 21(2B):1487-94. PubMed ID: 11396237
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
Chiappori AA; Haura E; Rodriguez FA; Boulware D; Kapoor R; Neuger AM; Lush R; Padilla B; Burton M; Williams C; Simon G; Antonia S; Sullivan DM; Bepler G
Clin Cancer Res; 2008 Mar; 14(5):1464-9. PubMed ID: 18316570
[TBL] [Abstract][Full Text] [Related]
9. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
Cohen RB; Langer CJ; Simon GR; Eisenberg PD; Hainsworth JD; Madajewicz S; Cosgriff TM; Pierce K; Xu H; Liau K; Healey D
Cancer Chemother Pharmacol; 2007 Jun; 60(1):81-9. PubMed ID: 17031646
[TBL] [Abstract][Full Text] [Related]
10. [Chemotherapy with high-dose carboplatin for inoperable non-small cell lung cancer].
Daido K; Arita K; Ejima T; Hirata T; Takahashi T; Oguri T; Yamamoto N; Hasegawa K; Yamakido M
Gan To Kagaku Ryoho; 1993 Oct; 20(13):1983-8. PubMed ID: 8215472
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
Seiwert TY; Connell PP; Mauer AM; Hoffman PC; George CM; Szeto L; Salgia R; Posther KE; Nguyen B; Haraf DJ; Vokes EE
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):515-22. PubMed ID: 17255273
[TBL] [Abstract][Full Text] [Related]
12. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation.
Belani CP; Barstis J; Perry MC; La Rocca RV; Nattam SR; Rinaldi D; Clark R; Mills GM
J Clin Oncol; 2003 Aug; 21(15):2933-9. PubMed ID: 12885812
[TBL] [Abstract][Full Text] [Related]
13. Paclitacxel and carboplatin in advanced non-small-cell lung cancer.
Huang PW; Gu YH; Lu KH; Shu YQ
Biomed Pharmacother; 2006 Dec; 60(10):698-700. PubMed ID: 17071050
[TBL] [Abstract][Full Text] [Related]
14. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
[TBL] [Abstract][Full Text] [Related]
15. [Cytokine in cancer chemotherapy--clinical trials of IL-3, IL-11 and thrombopoietin against thrombocytopenia].
Kudoh S; Yamada M
Gan To Kagaku Ryoho; 1998 Jan; 25(2):171-6. PubMed ID: 9474925
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
Miller AA; Al Omari A; Murry DJ; Case D
Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of non-small-cell lung cancer with paraplatin given by two different dosage calculation methods].
Gu LJ; Wu YL; Feng WN; Weng YM; Cheng C; Zhong WZ; Huang SH; Yang P
Zhonghua Zhong Liu Za Zhi; 2005 Jan; 27(1):29-32. PubMed ID: 15771794
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of combined radiation, paclitaxel and carboplatin for locally advanced non-small cell lung carcinoma.
Nguyen NP; Leonardo JM; Karlsson U; Vos P; Bullock L; Thomas P; Lepera P; Ludin A; Chu C; Salehpour M; Jendrasiak G; Sallah S
Anticancer Res; 2002; 22(6B):3429-35. PubMed ID: 12552935
[TBL] [Abstract][Full Text] [Related]
19. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response.
Vollmer RT; Govindan R; Graziano SL; Gamble G; Garst J; Kelley MJ; Christenson RH
Clin Cancer Res; 2003 May; 9(5):1728-33. PubMed ID: 12738727
[TBL] [Abstract][Full Text] [Related]
20. Dose-escalating and pharmacokinetic study of a weekly combination of paclitaxel and carboplatin for inoperable non-small cell lung cancer: JCOG 9910-DI.
Naoki K; Kunikane H; Fujii T; Tsujimura S; Hida N; Okamoto H; Watanabe K
Jpn J Clin Oncol; 2009 Sep; 39(9):569-75. PubMed ID: 19520687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
